CFTR Modulators: Impact on Fertility, Pregnancy, and Lactation in Women with Cystic Fibrosis

Overview

Journal J Clin Med

Specialty General Medicine

Date 2020 Aug 23

PMID 32825766

Citations 20

Authors

Jennifer L Taylor-Cousar

Affiliations

Soon will be listed here.

Abstract

Cystic fibrosis (CF) is a life-shortening genetic disorder caused by mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene. These mutations lead to abnormal ion transport in mucous membranes throughout the body, including in the respiratory and gastrointestinal and reproductive tracts. Improvements in care and therapy have led to substantial increases in the quantity and quality of life for those with CF. Consequently, women with CF are increasingly interested in having families. Although pregnancy was once discouraged for women with CF, at this point, even women with moderately severe lung disease can successfully navigate pregnancy. With the recent approval of a triple combination CFTR modulator therapy that improves lung function, nutritional status, and quality of life for people with a single copy of the most common CFTR mutation, it is expected that the number of women with CF who choose to become pregnant will continue to increase. Although animal reproduction models show no alarming signals for use during pregnancy at normal human doses, there is a paucity of human safety data in pregnancy and lactation. This review summarizes what is currently known about the impact of use of CFTR modulators on fertility, pregnancy, and lactation in women with CF.

Citing Articles

The CFTR K464N variant in fetuses potential increases premature birth risk in Chinese families.

Li J, Zhang L, Xi F, Lin C, Zhan Q, Zhou Q Hum Genomics. 2025; 19(1):25.

PMID: 40075526 PMC: 11905445. DOI: 10.1186/s40246-025-00736-7.

Exploring the dynamics of mixed-species biofilms involving Candida spp. and bacteria in cystic fibrosis.

Gourari-Bouzouina K, Boucherit-Otmani Z, Halla N, Seghir A, Baba Ahmed-Kazi Tani Z, Boucherit K Arch Microbiol. 2024; 206(6):255.

PMID: 38734793 DOI: 10.1007/s00203-024-03967-9.

Highly effective cystic fibrosis transmembrane conductance (regulator) modulator therapy: shifting the curve for most while leaving some further behind.

Chun S, Somers M, Burgener E Curr Opin Pediatr. 2024; 36(3):290-295.

PMID: 38411576 PMC: 11042992. DOI: 10.1097/MOP.0000000000001338.

Maternal, newborn and breast milk concentrations of elexacaftor/tezacaftor/ivacaftor in a F508del heterozygous woman with cystic fibrosis following successful pregnancy.

Ripani P, Mucci M, Pantano S, Di Sabatino M, Collini F, Ferri G Front Med (Lausanne). 2023; 10:1274303.

PMID: 38131041 PMC: 10734635. DOI: 10.3389/fmed.2023.1274303.

Ocular development after highly effective modulator treatment early in life.

Zhu Y, Li D, Reyes-Ortega F, Chinnery H, Schneider-Futschik E Front Pharmacol. 2023; 14:1265138.

PMID: 37795027 PMC: 10547496. DOI: 10.3389/fphar.2023.1265138.

References

Mainz J, Michl R, Beiersdorf N, Lorenz M, Schneider U, Groten T . Successful Pregnancy of a Patient with Cystic Fibrosis Genotype F508del/ F508del and Progressed Pulmonary Destruction on lumacaftor/ivacaftor. Klin Padiatr. 2019; 231(5):271-273. DOI: 10.1055/a-0973-8565. View

Taylor-Cousar J, Munck A, McKone E, van der Ent C, Moeller A, Simard C . Tezacaftor-Ivacaftor in Patients with Cystic Fibrosis Homozygous for Phe508del. N Engl J Med. 2017; 377(21):2013-2023. DOI: 10.1056/NEJMoa1709846. View

Heijerman H, McKone E, Downey D, Van Braeckel E, Rowe S, Tullis E . Efficacy and safety of the elexacaftor plus tezacaftor plus ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del mutation: a double-blind, randomised, phase 3 trial. Lancet. 2019; 394(10212):1940-1948. PMC: 7571408. DOI: 10.1016/S0140-6736(19)32597-8. View

Ramsey B, Davies J, McElvaney N, Tullis E, Bell S, Drevinek P . A CFTR potentiator in patients with cystic fibrosis and the G551D mutation. N Engl J Med. 2011; 365(18):1663-72. PMC: 3230303. DOI: 10.1056/NEJMoa1105185. View

Tizzano E, Silver M, Chitayat D, Benichou J, Buchwald M . Differential cellular expression of cystic fibrosis transmembrane regulator in human reproductive tissues. Clues for the infertility in patients with cystic fibrosis. Am J Pathol. 1994; 144(5):906-14. PMC: 1887367. View

Patel E, Swamy G, Heine R, Kuller J, James A, Grotegut C . Medical and obstetric complications among pregnant women with cystic fibrosis. Am J Obstet Gynecol. 2014; 212(1):98.e1-9. DOI: 10.1016/j.ajog.2014.07.018. View

Accurso F, Rowe S, Clancy J, Boyle M, Dunitz J, Durie P . Effect of VX-770 in persons with cystic fibrosis and the G551D-CFTR mutation. N Engl J Med. 2010; 363(21):1991-2003. PMC: 3148255. DOI: 10.1056/NEJMoa0909825. View

Ladores S, Bray L, Brown J . Two Unanticipated Pregnancies While on Cystic Fibrosis Gene-Specific Drug Therapy. J Patient Exp. 2020; 7(1):4-7. PMC: 7036671. DOI: 10.1177/2374373519826556. View

Edenborough F, Borgo G, Knoop C, Lannefors L, Mackenzie W, Madge S . Guidelines for the management of pregnancy in women with cystic fibrosis. J Cyst Fibros. 2007; 7 Suppl 1:S2-32. DOI: 10.1016/j.jcf.2007.10.001. View

10.

Jones G, Walshaw M . Potential impact on fertility of new systemic therapies for cystic fibrosis. Paediatr Respir Rev. 2015; 16 Suppl 1:25-7. DOI: 10.1016/j.prrv.2015.07.013. View

11.

Vekaria S, Popowicz N, White S, Mulrennan S . To be or not to be on CFTR modulators during pregnancy: Risks to be considered. J Cyst Fibros. 2019; 19(2):e7-e8. DOI: 10.1016/j.jcf.2019.12.004. View

12.

Trimble A, McKinzie C, Terrell M, Stringer E, Esther Jr C . Measured fetal and neonatal exposure to Lumacaftor and Ivacaftor during pregnancy and while breastfeeding. J Cyst Fibros. 2018; 17(6):779-782. PMC: 6354249. DOI: 10.1016/j.jcf.2018.05.009. View

13.

Van Goor F, Hadida S, Grootenhuis P, Burton B, Cao D, Neuberger T . Rescue of CF airway epithelial cell function in vitro by a CFTR potentiator, VX-770. Proc Natl Acad Sci U S A. 2009; 106(44):18825-30. PMC: 2773991. DOI: 10.1073/pnas.0904709106. View

14.

Middleton P, Gade E, Aguilera C, Mackillop L, Button B, Coleman C . ERS/TSANZ Task Force Statement on the management of reproduction and pregnancy in women with airways diseases. Eur Respir J. 2019; 55(2). DOI: 10.1183/13993003.01208-2019. View

15.

Ahmad A, Ahmed A, Patrizio P . Cystic fibrosis and fertility. Curr Opin Obstet Gynecol. 2013; 25(3):167-72. DOI: 10.1097/GCO.0b013e32835f1745. View

16.

Cohen L, di SantAgnese P, FRIEDLANDER J . Cystic fibrosis and pregnancy. A national survey. Lancet. 1980; 2(8199):842-4. DOI: 10.1016/s0140-6736(80)90183-x. View

17.

Godfrey E, Mody S, Schwartz M, Heltshe S, Taylor-Cousar J, Jain R . Contraceptive use among women with cystic fibrosis: A pilot study linking reproductive health questions to the Cystic Fibrosis Foundation National Patient Registry. Contraception. 2020; 101(6):420-426. PMC: 7494372. DOI: 10.1016/j.contraception.2020.02.006. View

18.

Schechter M, Quittner A, Konstan M, Millar S, Pasta D, McMullen A . Long-term effects of pregnancy and motherhood on disease outcomes of women with cystic fibrosis. Ann Am Thorac Soc. 2013; 10(3):213-9. DOI: 10.1513/AnnalsATS.201211-108OC. View

19.

Kroon M, Akkerman-Nijland A, Rottier B, Koppelman G, Akkerman O, Touw D . Drugs during pregnancy and breast feeding in women diagnosed with Cystic Fibrosis - An update. J Cyst Fibros. 2017; 17(1):17-25. DOI: 10.1016/j.jcf.2017.11.009. View

20.

Goss C, Rubenfeld G, Otto K, Aitken M . The effect of pregnancy on survival in women with cystic fibrosis. Chest. 2003; 124(4):1460-8. DOI: 10.1378/chest.124.4.1460. View